profit from every $100 of sales.
$0$100
Roivant Sciences
$39.53-1.15% today
+92.3% in 1 year
1-year low $20.101-year high $41.85
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2021 to 2026.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Roivant Sciences sold, what it kept, and what it did with the cash.
Sales went from $31.5 million in 2023 to $8.26 million in 2026, with -$300 million of profit last year.
SalesProfit
Roivant Sciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Roivant Sciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Roivant Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 24 | 55 | 32 | 33 | 29 | 8 | |
| – | – | 28 | 31 | 28 | 7 | |
| – | – | -809 | -825 | -1,114 | -1,285 | |
| – | – | -790 | -803 | -1,100 | -1,282 | |
| -809 | -845 | -1,009 | 4,349 | -172 | -300 | |
| -1.28 | -1.26 | -1.42 | 5.23 | -0.24 | -0.54 | |
| – | – | 90.4% | 95.1% | 96.9% | 84.4% | |
| – | – | -2,565.9% | -2,521.7% | -3,833.3% | -15,560.6% | |
| -3,400.9% | -1,528.9% | -3,200.2% | 13,294.2% | -592.0% | -3,629.2% |
Balance sheet
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Total assets | 2,590 | 2,585 | 2,390 | 7,222 | 5,437 | 5,709 |
| Cash | 2,055 | 2,060 | 1,677 | 6,495 | 2,715 | 1,419 |
| Total debt | – | – | 481 | 54 | 100 | 107 |
| Total liabilities | 528 | 524 | 782 | 774 | 250 | 416 |
| 1,798 | 1,657 | 1,158 | 5,969 | 4,688 | 4,527 | |
| – | 670 | 713 | 831 | 725 | 694 | |
| – | – | -39.0% | -10.8% | -18.4% | -21.9% | |
| -45.0% | -51.0% | -87.2% | 72.9% | -3.7% | -6.6% |
Cash flow
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| -552 | -678 | -843 | -765 | -839 | -750 | |
| 6 | 17 | 13 | 1 | 5 | 8 | |
| -558 | -695 | -856 | -767 | -844 | -759 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | 0 | 0 | 1,293 | 320 | |
| 85 | 565 | 218 | 200 | 289 | 346 |
Valuation
- –
- –
- –
- 4.8×
- 3,467.5×
- –
- –
- -2.6%
- -1.0%
- 0.0%
Profitability
- 84.4%
- -15,560.6%
- -3,629.2%
- -7,627.1%
- -23.9%
- -15.8%
- -18.3%
- -15.5%
- -24.0%
- 4,719.0%
Growth
- −19.1%
- –
- −10.1%
- –
- +1.5%
Financial health
- -1.0×
- 0.05
- 4.0%
- –
- 30.66
- 30.66
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 17%of 952
Bottom 5%of 886
Bottom 25%of 987
What analysts expect
- Average price target
- $33.20
- Range
- $30.00 – $40.00
- 5 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 6, 2026 | -0.24 | -0.30 | +19.9% |
| Nov 10, 2025 | -0.28 | -0.32 | +12.4% |
| Aug 11, 2025 | -0.18 | -0.25 | +27.9% |
| May 29, 2025 | -0.22 | -0.26 | +16.5% |
| Feb 10, 2025 | -0.13 | -0.24 | +45.8% |
| Nov 12, 2024 | -0.29 | -0.25 | −17.4% |
| Aug 8, 2024 | -0.18 | -0.24 | +26.0% |
| May 30, 2024 | -0.23 | -0.26 | +13.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
42No pass
Philip Fisher
55No pass
Peter Lynch
41No pass
Joel Greenblatt
2No pass
Charlie Munger
57No pass
Terry Smith
50No pass
Questions about Roivant Sciences
Is Roivant Sciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Roivant Sciences AI analysis
What does Roivant Sciences do?
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. It is in Biotechnology, based in London, United Kingdom, with 721 employees.
Does Roivant Sciences pay a dividend?
No. Roivant Sciences does not pay a dividend at the moment; in 2026 it returned $320 million to shareholders by buying back its own shares.
Is Roivant Sciences stock halal?
Questionable. Roivant Sciences sits in a grey zone: it has almost no revenue, so its interest as a share of revenue means little. How we check
How has Roivant Sciences stock done over the past year?
Up 92.3% over the past twelve months, to $39.53. It traded between $20.10 and $41.85 and is 5.5% below its high.
Who are Roivant Sciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Roivant Sciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.